FindTrial
Sign In

Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications

Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-16008147
Enrollment
Unknown
Registered
2016-03-24
Start date
2014-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular glaucoma

Interventions

IVR group:intravitreal ranibizumab (IVR) injection combined trabeculectomy
Ahmed group:surgery of Ahmed valve implantation

Sponsors

the First Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
33 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. aged >20 years; 2. diagnosed as NVG with rubeosis; 3. IOP>21mmHg with the maximum use of anti-glaucoma drugs.

Exclusion criteria

Exclusion criteria: 1. active ocular infection; 2. previous glaucoma filtering surgery; 3. previous anti-VEGF treatment; 4. any contraindication of intraocular injection or surgery, such as high risk of bleeding, pregnancy, and infection.

Design outcomes

Primary

MeasureTime frame
IOP;—

Secondary

MeasureTime frame
BCVA;Pain scores;new vessels of iris;complications;—

Countries

China

Contacts

Public ContactLan Liu

the First Affiliated Hospital, College of Medicine, Zhejiang University

flowingblue@126.com+86 0571 87236791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 13, 2026